SCHEMBL30714643

SCHEMBL30714643

Cn1nc2ccc(OCc3cccnc3C(F)(F)F)cc2c1C(=O)NCc1cccc(O)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.36
CD38 P28907 1/20 0.35
KLKB1 P03952 1/20 0.35
SCN9A Q15858 1/20 0.34
MAPK1 P28482 2/20 0.34
HTT P42858 1/20 0.34
OPRL1 P41146 1/20 0.34
MCHR1 Q99705 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
ALDH1A1 P00352 5/20 0.33
HPGD P15428 4/20 0.33
KDM4E B2RXH2 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714607 0.83 MMP13 (0.47) PTGER4ALDH1A1SMN1; SMN2KMT2AMMP13
SCHEMBL30714600 0.82 TYK2 (0.38) PTGER4CD38KLKB1OPRL1MCHR1
SCHEMBL30714731 0.82 HPGDS (0.41) MAPK1ALDH1A1HPGDKDM4ECYP1A2
SCHEMBL26696085 0.81 NPC1 (0.37) CD38KLKB1HTTOPRL1MCHR1
SCHEMBL30714557 0.81 NPC1 (0.37) CD38KLKB1HTTOPRL1MCHR1
SCHEMBL30714722 0.81 KDM4C (0.39) HTTOPRL1SMN1; SMN2LMNAKMT2A
SCHEMBL26696047 0.81 KDM4C (0.39) HTTOPRL1SMN1; SMN2LMNAKMT2A
SCHEMBL30714582 0.81 CNR2 (0.37) CD38KLKB1OPRL1MCHR1CYP2C9
SCHEMBL30714749 0.81 OPRL1 (0.35) CD38KLKB1HTTOPRL1MCHR1
SCHEMBL30656056 0.80 CD38 (0.37) CD38KLKB1SCN9AMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 PTGER4 533/4885CD38 1480/4885KLKB1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.